Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2014

Open Access 01-12-2014 | Original investigation

Omentin changes following bariatric surgery and predictive links with biomarkers for risk of cardiovascular disease

Authors: Marc Lapointe, Paul Poirier, Julie Martin, Marjorie Bastien, Audrey Auclair, Katherine Cianflone

Published in: Cardiovascular Diabetology | Issue 1/2014

Login to get access

Abstract

Background

Although no receptor has yet been identified, changes in circulating levels of the adipokine designated as Omentin have been demonstrated in obesity and related comorbidities such as cardiovascular disease, insulin resistance, metabolic syndrome and chronic inflammation.

Methods

Changes in Omentin levels at 1 and 5 days and 6 and 12 months in response to biliopancreatic diversion with duodenal switch bariatric surgery were evaluated, specifically to investigate if changes preceded gain of insulin sensitivity.

Results

Pre-operative plasma Omentin was not different between men (n = 18) vs women (n = 48), or diabetic status but correlated with body mass index (BMI). Altogether, Omentin increased as early as 24-h post-surgery, with changes maintained up to 1-year. Fifty-nine percent of subjects increased Omentin >10% by 24-H following surgery (OmentinINC p < 0.0001), while 18% of subjects decreased (OmentinDEC p < 0.0001), with changes maintained throughout one-year. These two groups had comparable age, sex distribution, diabetes, BMI, waist circumference and fat mass, however OmentinDEC had elevated levels of cardiovascular risk markers; homocysteine (p = 0.019), NT-proBNP (p = 0.006) and total bilirubin (p = 0.0001) while red blood cell (RBC) count was lower (p = 0.0005) over the one-year period. Omentin levels at 1-DAY also correlated with immune parameters (white blood cell count, % neutrophil, % monocytes, % lymphocytes).

Conclusion

OmentinDEC at 1 day following surgery may be a marker of cardiovascular “at-risk” group before weight loss or insulin sensitivity restoration.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jaikanth C, Gurumurthy P, Cherian KM, Indhumathi T: Emergence of omentin as a pleiotropic adipocytokine. Exp Clin Endocrinol Diabetes. 2013, 121: 377-383. 10.1055/s-0033-1345123.CrossRefPubMed Jaikanth C, Gurumurthy P, Cherian KM, Indhumathi T: Emergence of omentin as a pleiotropic adipocytokine. Exp Clin Endocrinol Diabetes. 2013, 121: 377-383. 10.1055/s-0033-1345123.CrossRefPubMed
2.
go back to reference Schäffler A, Neumeier M, Herfarth H, Fürst A, Schölmerich J, Büchler C: Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta. 2005, 1732: 96-102. 10.1016/j.bbaexp.2005.11.005.CrossRefPubMed Schäffler A, Neumeier M, Herfarth H, Fürst A, Schölmerich J, Büchler C: Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta. 2005, 1732: 96-102. 10.1016/j.bbaexp.2005.11.005.CrossRefPubMed
3.
go back to reference Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC, Gong DW: Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab. 2006, 290: E1253-E1261. 10.1152/ajpendo.00572.2004.CrossRefPubMed Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC, Gong DW: Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab. 2006, 290: E1253-E1261. 10.1152/ajpendo.00572.2004.CrossRefPubMed
4.
go back to reference Kazama K, Usui T, Okada M, Hara Y, Yamawaki H: Omentin plays an anti-inflammatory role through inhibition of TNF-?-induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol. 2012, 686: 116-123. 10.1016/j.ejphar.2012.04.033.CrossRefPubMed Kazama K, Usui T, Okada M, Hara Y, Yamawaki H: Omentin plays an anti-inflammatory role through inhibition of TNF-?-induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol. 2012, 686: 116-123. 10.1016/j.ejphar.2012.04.033.CrossRefPubMed
5.
go back to reference de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, Fried SK, Gong DW, Shuldiner AR, Pollin TI, McLenithan JC: Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007, 56: 1655-1661. 10.2337/db06-1506.CrossRefPubMed de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, Fried SK, Gong DW, Shuldiner AR, Pollin TI, McLenithan JC: Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007, 56: 1655-1661. 10.2337/db06-1506.CrossRefPubMed
6.
go back to reference Shibata R, Ouchi N, Takahashi R, Terakura Y, Ohashi K, Ikeda N, Higuchi A, Terasaki H, Kihara S, Murohara T: Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr. 2012, 4: 37-10.1186/1758-5996-4-37.PubMedCentralCrossRefPubMed Shibata R, Ouchi N, Takahashi R, Terakura Y, Ohashi K, Ikeda N, Higuchi A, Terasaki H, Kihara S, Murohara T: Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr. 2012, 4: 37-10.1186/1758-5996-4-37.PubMedCentralCrossRefPubMed
7.
go back to reference Jialal I, Devaraj S, Kaur H, Adams-Huet B, Bremer AA: Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. J Clin Endocrinol Metab. 2013, 98: E514-E517. 10.1210/jc.2012-3673.CrossRefPubMed Jialal I, Devaraj S, Kaur H, Adams-Huet B, Bremer AA: Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. J Clin Endocrinol Metab. 2013, 98: E514-E517. 10.1210/jc.2012-3673.CrossRefPubMed
8.
go back to reference Liu R, Wang X, Bu P: Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract. 2011, 93: 21-25. 10.1016/j.diabres.2011.03.001.CrossRefPubMed Liu R, Wang X, Bu P: Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract. 2011, 93: 21-25. 10.1016/j.diabres.2011.03.001.CrossRefPubMed
9.
go back to reference Shibata R, Ouchi N, Kikuchi R, Takahashi R, Takeshita K, Kataoka Y, Ohashi K, Ikeda N, Kihara S, Murohara T: Circulating omentin is associated with coronary artery disease in men. Atherosclerosis. 2011, 219: 811-814. 10.1016/j.atherosclerosis.2011.08.017.CrossRefPubMed Shibata R, Ouchi N, Kikuchi R, Takahashi R, Takeshita K, Kataoka Y, Ohashi K, Ikeda N, Kihara S, Murohara T: Circulating omentin is associated with coronary artery disease in men. Atherosclerosis. 2011, 219: 811-814. 10.1016/j.atherosclerosis.2011.08.017.CrossRefPubMed
10.
go back to reference Yoo HJ, Hwang SY, Hong HC, Choi HY, Yang SJ, Seo JA, Kim SG, Kim NH, Choi KM, Choi DS, Baik SH: Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc Diabetol. 2011, 10: 103-10.1186/1475-2840-10-103.PubMedCentralCrossRefPubMed Yoo HJ, Hwang SY, Hong HC, Choi HY, Yang SJ, Seo JA, Kim SG, Kim NH, Choi KM, Choi DS, Baik SH: Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc Diabetol. 2011, 10: 103-10.1186/1475-2840-10-103.PubMedCentralCrossRefPubMed
11.
go back to reference Pan HY, Guo L, Li Q: Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract. 2010, 88: 29-33. 10.1016/j.diabres.2010.01.013.CrossRefPubMed Pan HY, Guo L, Li Q: Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract. 2010, 88: 29-33. 10.1016/j.diabres.2010.01.013.CrossRefPubMed
12.
go back to reference El-Mesallamy HO, El-Derany MO, Hamdy NM: Serum omentin-1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischaemic heart disease. Diabet Med. 2011, 28: 1194-1200. 10.1111/j.1464-5491.2011.03353.x.CrossRefPubMed El-Mesallamy HO, El-Derany MO, Hamdy NM: Serum omentin-1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischaemic heart disease. Diabet Med. 2011, 28: 1194-1200. 10.1111/j.1464-5491.2011.03353.x.CrossRefPubMed
13.
go back to reference Moreno-Navarrete JM, Catalán V, Ortega F, Gómez-Ambrosi J, Ricart W, Frühbeck G: Fernández-Real JM: Circulating omentin concentration increases after weight loss. Nutr Metab (Lond). 2010, 7: 27-10.1186/1743-7075-7-27.CrossRef Moreno-Navarrete JM, Catalán V, Ortega F, Gómez-Ambrosi J, Ricart W, Frühbeck G: Fernández-Real JM: Circulating omentin concentration increases after weight loss. Nutr Metab (Lond). 2010, 7: 27-10.1186/1743-7075-7-27.CrossRef
14.
go back to reference Saremi A, Asghari M, Ghorbani A: Effects of aerobic training on serum omentin-1 and cardiometabolic risk factors in overweight and obese men. J Sports Sci. 2010, 28: 993-998. 10.1080/02640414.2010.484070.CrossRefPubMed Saremi A, Asghari M, Ghorbani A: Effects of aerobic training on serum omentin-1 and cardiometabolic risk factors in overweight and obese men. J Sports Sci. 2010, 28: 993-998. 10.1080/02640414.2010.484070.CrossRefPubMed
15.
go back to reference Tan BK, Adya R, Farhatullah S, Lewandowski KC, O’Hare P, Lehnert H, Randeva HS: Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes. 2008, 57: 801-808. 10.2337/db07-0990.CrossRefPubMed Tan BK, Adya R, Farhatullah S, Lewandowski KC, O’Hare P, Lehnert H, Randeva HS: Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes. 2008, 57: 801-808. 10.2337/db07-0990.CrossRefPubMed
16.
go back to reference Poirier P, Cornier MA, Mazzone T, Stiles S, Cummings S, Klein S, McCullough PA, Ren Fielding C, Franklin BA: American heart association obesity committee of the council on nutrition, physical activity, and metabolism. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation. 2011, 123: 1683-1701. 10.1161/CIR.0b013e3182149099.CrossRefPubMed Poirier P, Cornier MA, Mazzone T, Stiles S, Cummings S, Klein S, McCullough PA, Ren Fielding C, Franklin BA: American heart association obesity committee of the council on nutrition, physical activity, and metabolism. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation. 2011, 123: 1683-1701. 10.1161/CIR.0b013e3182149099.CrossRefPubMed
17.
go back to reference Brethauer SA, Aminian A, Romero-Talamás H, Batayyah E, Mackey J, Kennedy L, Kashyap SR, Kirwan JP, Rogula T, Kroh M, Chand B, Schauer PR: Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013, 258: 628-636.PubMedCentralPubMed Brethauer SA, Aminian A, Romero-Talamás H, Batayyah E, Mackey J, Kennedy L, Kashyap SR, Kirwan JP, Rogula T, Kroh M, Chand B, Schauer PR: Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013, 258: 628-636.PubMedCentralPubMed
18.
go back to reference Sjöström L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden Å, Bouchard C, Carlsson B, Karason K, Lönroth H, Näslund I, Sjöström E, Taube M, Wedel H, Svensson PA, Sjöholm K, Carlsson LM: Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014, 311: 2297-2304. 10.1001/jama.2014.5988.CrossRefPubMed Sjöström L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden Å, Bouchard C, Carlsson B, Karason K, Lönroth H, Näslund I, Sjöström E, Taube M, Wedel H, Svensson PA, Sjöholm K, Carlsson LM: Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014, 311: 2297-2304. 10.1001/jama.2014.5988.CrossRefPubMed
19.
go back to reference Habib P, Scrocco JD, Terek M, Vanek V, Mikolich JR: Effects of bariatric surgery on inflammatory, functional and structural markers of coronary atherosclerosis. Am J Cardiol. 2009, 104: 1251-1255. 10.1016/j.amjcard.2009.06.042.CrossRefPubMed Habib P, Scrocco JD, Terek M, Vanek V, Mikolich JR: Effects of bariatric surgery on inflammatory, functional and structural markers of coronary atherosclerosis. Am J Cardiol. 2009, 104: 1251-1255. 10.1016/j.amjcard.2009.06.042.CrossRefPubMed
20.
go back to reference Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K: Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004, 292: 1724-1737. 10.1001/jama.292.14.1724.CrossRefPubMed Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K: Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004, 292: 1724-1737. 10.1001/jama.292.14.1724.CrossRefPubMed
21.
go back to reference Munkonda MN, Martin J, Poirier P, Carrington A, Biron S, Lebel S, Cianflone K: Acylation stimulating protein reduction precedes insulin sensitization after BPD-DS bariatric surgery in severely obese women. Nutr Diabetes. 2012, 2: e41-10.1038/nutd.2012.13.PubMedCentralCrossRefPubMed Munkonda MN, Martin J, Poirier P, Carrington A, Biron S, Lebel S, Cianflone K: Acylation stimulating protein reduction precedes insulin sensitization after BPD-DS bariatric surgery in severely obese women. Nutr Diabetes. 2012, 2: e41-10.1038/nutd.2012.13.PubMedCentralCrossRefPubMed
22.
go back to reference Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18: 499-502.PubMed Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18: 499-502.PubMed
23.
go back to reference Hanusch-Enserer U, Hermann KM, Cauza E, Spak M, Mähr B, Dunky A, Rosen HR, Köller U, Prager R: Effect of gastric banding on aminoterminal pro-brain natriuretic peptide in the morbidly obese. Obes Res. 2003, 11: 695-698. 10.1038/oby.2003.99.CrossRefPubMed Hanusch-Enserer U, Hermann KM, Cauza E, Spak M, Mähr B, Dunky A, Rosen HR, Köller U, Prager R: Effect of gastric banding on aminoterminal pro-brain natriuretic peptide in the morbidly obese. Obes Res. 2003, 11: 695-698. 10.1038/oby.2003.99.CrossRefPubMed
24.
go back to reference Görmüs U, Ozmen D, Ozmen B, Parildar Z, Ozdogan O, Mutaf I, Bayindir O: Serum N-terminal-pro-brain natriuretic peptide (NT-pro-BNP) and homocysteine levels in type 2 diabetic patients with asymptomatic left ventricular diastolic dysfunction. Diabetes Res Clin Pract. 2010, 87: 51-56. 10.1016/j.diabres.2009.10.010.CrossRefPubMed Görmüs U, Ozmen D, Ozmen B, Parildar Z, Ozdogan O, Mutaf I, Bayindir O: Serum N-terminal-pro-brain natriuretic peptide (NT-pro-BNP) and homocysteine levels in type 2 diabetic patients with asymptomatic left ventricular diastolic dysfunction. Diabetes Res Clin Pract. 2010, 87: 51-56. 10.1016/j.diabres.2009.10.010.CrossRefPubMed
25.
go back to reference MacGowan GA, Neely D, Peaston R, Wrightson N, Parry G: Evaluation of NT-proBNP to predict outcomes in advanced heart failure. Int J Clin Pract. 2010, 64: 892-899. 10.1111/j.1742-1241.2010.02388.x.CrossRefPubMed MacGowan GA, Neely D, Peaston R, Wrightson N, Parry G: Evaluation of NT-proBNP to predict outcomes in advanced heart failure. Int J Clin Pract. 2010, 64: 892-899. 10.1111/j.1742-1241.2010.02388.x.CrossRefPubMed
26.
go back to reference Ahluwalia N, Blacher J, Szabo de Edelenyi F, Faure P, Julia C, Hercberg S, Galan P: Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease. Atherosclerosis. 2013, 228: 478-484. 10.1016/j.atherosclerosis.2013.03.017.CrossRefPubMed Ahluwalia N, Blacher J, Szabo de Edelenyi F, Faure P, Julia C, Hercberg S, Galan P: Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease. Atherosclerosis. 2013, 228: 478-484. 10.1016/j.atherosclerosis.2013.03.017.CrossRefPubMed
27.
go back to reference Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M: Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Clin Proc. 2008, 83: 1203-1212. 10.4065/83.11.1203.CrossRef Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M: Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Clin Proc. 2008, 83: 1203-1212. 10.4065/83.11.1203.CrossRef
28.
go back to reference Cho HC: The relationship among homocysteine, bilirubin, and diabetic retinopathy. Diab Metab J. 2011, 35: 595-601. 10.4093/dmj.2011.35.6.595.CrossRef Cho HC: The relationship among homocysteine, bilirubin, and diabetic retinopathy. Diab Metab J. 2011, 35: 595-601. 10.4093/dmj.2011.35.6.595.CrossRef
29.
go back to reference Tzotzas T, Evangelou P, Kiortsis DN: Obesity, weight loss and conditional cardiovascular risk factors. Obes Rev. 2011, 12: e282-e289. 10.1111/j.1467-789X.2010.00807.x.CrossRefPubMed Tzotzas T, Evangelou P, Kiortsis DN: Obesity, weight loss and conditional cardiovascular risk factors. Obes Rev. 2011, 12: e282-e289. 10.1111/j.1467-789X.2010.00807.x.CrossRefPubMed
30.
go back to reference Biegus J, Zymlinski R, Sokolski M, Nawrocka S, Siwolowski P, Szachniewicz J, Jankowska EA, Banasiak W, Ponikowski P: Liver function tests in patients with acute heart failure. Pol Arch Med Wewn. 2012, 122: 471-479.PubMed Biegus J, Zymlinski R, Sokolski M, Nawrocka S, Siwolowski P, Szachniewicz J, Jankowska EA, Banasiak W, Ponikowski P: Liver function tests in patients with acute heart failure. Pol Arch Med Wewn. 2012, 122: 471-479.PubMed
31.
go back to reference Onat A, Can G, Örnek E, Çiçek G, Ayhan E, Dogan Y: Serum Y-glutamyltransferase: independent predictor of risk of diabetes, hypertension, metabolic syndrome, and coronary disease. Obesity (Silver Spring). 2012, 20: 842-848. 10.1038/oby.2011.136.CrossRef Onat A, Can G, Örnek E, Çiçek G, Ayhan E, Dogan Y: Serum Y-glutamyltransferase: independent predictor of risk of diabetes, hypertension, metabolic syndrome, and coronary disease. Obesity (Silver Spring). 2012, 20: 842-848. 10.1038/oby.2011.136.CrossRef
32.
go back to reference Giral P, Ratziu V, Couvert P, Carrié A, Kontush A, Girerd X, Chapman MJ: Plasma bilirubin and gamma-glutamyltransferase activity are inversely related in dyslipidemic patients with metabolic syndrome: relevance to oxidative stress. Atherosclerosis. 2010, 210: 607-613. 10.1016/j.atherosclerosis.2009.12.026.CrossRefPubMed Giral P, Ratziu V, Couvert P, Carrié A, Kontush A, Girerd X, Chapman MJ: Plasma bilirubin and gamma-glutamyltransferase activity are inversely related in dyslipidemic patients with metabolic syndrome: relevance to oxidative stress. Atherosclerosis. 2010, 210: 607-613. 10.1016/j.atherosclerosis.2009.12.026.CrossRefPubMed
33.
go back to reference Narumi T, Watanabe T, Kadowaki S, Kinoshita D, Yokoyama M, Honda Y, Otaki Y, Nishiyama S, Takahashi H, Arimoto T, Shishido T, Miyamoto T, Kubota I: Impact of serum omentin-1 levels on cardiac prognosis in patients with heart failure. Cardiovasc Diabetol. 2014, 13: 84-10.1186/1475-2840-13-84.PubMedCentralCrossRefPubMed Narumi T, Watanabe T, Kadowaki S, Kinoshita D, Yokoyama M, Honda Y, Otaki Y, Nishiyama S, Takahashi H, Arimoto T, Shishido T, Miyamoto T, Kubota I: Impact of serum omentin-1 levels on cardiac prognosis in patients with heart failure. Cardiovasc Diabetol. 2014, 13: 84-10.1186/1475-2840-13-84.PubMedCentralCrossRefPubMed
34.
go back to reference Kataoka Y, Shibata R, Ohashi K, Kambara T, Enomoto T, Uemura Y, Ogura Y, Yuasa D, Matsuo K, Nagata T, Oba T, Yasukawa H, Numaguchi Y, Sone T, Murohara T, Ouchi N: Omentin prevents myocardial ischemic injury through AMPK- and Akt-dependent mechanisms. J Am Coll Cardiol. 2014, 63: 2722-33. 10.1016/j.jacc.2014.03.032.CrossRefPubMed Kataoka Y, Shibata R, Ohashi K, Kambara T, Enomoto T, Uemura Y, Ogura Y, Yuasa D, Matsuo K, Nagata T, Oba T, Yasukawa H, Numaguchi Y, Sone T, Murohara T, Ouchi N: Omentin prevents myocardial ischemic injury through AMPK- and Akt-dependent mechanisms. J Am Coll Cardiol. 2014, 63: 2722-33. 10.1016/j.jacc.2014.03.032.CrossRefPubMed
35.
go back to reference Tsuji S, Uehori J, Matsumoto M, Suzuki Y, Matsuhisa A, Toyoshima K, Seya T: Human intelectin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall. J Biol Chem. 2001, 276: 23456-23463. 10.1074/jbc.M103162200.CrossRefPubMed Tsuji S, Uehori J, Matsumoto M, Suzuki Y, Matsuhisa A, Toyoshima K, Seya T: Human intelectin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall. J Biol Chem. 2001, 276: 23456-23463. 10.1074/jbc.M103162200.CrossRefPubMed
36.
go back to reference Caricilli AM, Saad MJ: Gut microbiota composition and its effects on obesity and insulin resistance. Curr Opin Clin Nutr Metab Care. 2014, 17: 312-318. 10.1097/MCO.0000000000000067.CrossRefPubMed Caricilli AM, Saad MJ: Gut microbiota composition and its effects on obesity and insulin resistance. Curr Opin Clin Nutr Metab Care. 2014, 17: 312-318. 10.1097/MCO.0000000000000067.CrossRefPubMed
37.
go back to reference Erejuwa OO, Sulaiman SA, Ab Wahab MS: Modulation of gut microbiota in the management of metabolic disorders: the prospects and challenges. Int J Mol Sci. 2014, 15: 4158-4188. 10.3390/ijms15034158.PubMedCentralCrossRefPubMed Erejuwa OO, Sulaiman SA, Ab Wahab MS: Modulation of gut microbiota in the management of metabolic disorders: the prospects and challenges. Int J Mol Sci. 2014, 15: 4158-4188. 10.3390/ijms15034158.PubMedCentralCrossRefPubMed
38.
go back to reference Onat A, Can G: Enhanced proinflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharm Des. 2014, 20: 575-584. 10.2174/138161282004140213145551.CrossRefPubMed Onat A, Can G: Enhanced proinflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharm Des. 2014, 20: 575-584. 10.2174/138161282004140213145551.CrossRefPubMed
Metadata
Title
Omentin changes following bariatric surgery and predictive links with biomarkers for risk of cardiovascular disease
Authors
Marc Lapointe
Paul Poirier
Julie Martin
Marjorie Bastien
Audrey Auclair
Katherine Cianflone
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2014
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-014-0124-9

Other articles of this Issue 1/2014

Cardiovascular Diabetology 1/2014 Go to the issue